A new hydrophilic biodegradable ureteral stent restrain encrustation both in vitro and in vivo
Source abstract
Abstract
Ureteral stents have been widely used as biomedical devices to treat some urological diseases for several decades. However, the encrustation complications hamper the long-time clinical use of the ureteral stents. In this work, a new type of biodegradable material for the ureteral stents, methoxypoly(ethylene glycol)-block-poly(L-lactide-ran-Ɛ-caprolactone) (mPEG-PLACL), is evaluated to overcome this problem. The results show that the hydrophilicity and degradation rate in artificial urine of mPEG-PLACL are both significantly increased. It is worth noting that the mPEG-PLACL shows a lower amount of encrustation after immersing the stents in the dynamic urinary extracorporeal circulation (DUEC) model for 7 days. In addition, 71% Ca and 92% Mg are inhibited in vivo by quantitative analysis. Pathological analysis exhibit that the mPEG-PLACL cause less diffuse mucosal hyperplasia after 7 weeks of implantation. All the results indicate that this new type of biodegradable material had an excellent potential for the ureteral stents in the future.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Ureteral procedures and complications · Infectious Aortic and Vascular Conditions · Kidney Stones and Urolithiasis Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Chengdu Institute of Organic Chemistry CAS, Chengdu, China
Funding
Department of Science and Technology of Sichuan Province · West Light Foundation of the Chinese Academy of Sciences
References (67)
Show source-provided references
1. 10.1016/j.msec.2016.11.12510.1016/j.msec.2016.11.125 ↗
2. 10.1016/0142-9612(96)89780-810.1016/0142-9612(96)89780-8 ↗
3. 10.1016/j.juro.2010.11.07310.1016/j.juro.2010.11.073 ↗
4. 10.1177/08853282970120020410.1177/088532829701200204 ↗
5. 10.1159/00004601510.1159/000046015 ↗
6. Urologia · 2011 · 81 · 93
7. 10.1111/j.1532-5415.1994.tb06513.x10.1111/j.1532-5415.1994.tb06513.x ↗
8. 10.1371/journal.pone.017211310.1371/journal.pone.0172113 ↗
9. 10.1016/j.bpj.2010.11.07810.1016/j.bpj.2010.11.078 ↗
10. 10.1063/1.505937010.1063/1.5059370 ↗
11. 10.3390/mi1104040810.3390/mi11040408 ↗
12. 10.1016/j.apsusc.2017.06.31410.1016/j.apsusc.2017.06.314 ↗
13. Razvi H. Ureteral stent coatings: What's here and what's coming. In: AIP Conference Proceedings on AIP RENAL STONE DISEASE 2: 2nd international urolithiasis research symposium (ed A P Evan), Indianapolis, America, 17-18 April 2008, volume 1049, pp.182-185. New York: AIP.10.1063/1.2998018 ↗
14. 10.1016/j.eururo.2005.07.00910.1016/j.eururo.2005.07.009 ↗
15. 10.1097/00005392-199502000-0001510.1097/00005392-199502000-00015 ↗
16. 10.1002/(SICI)1097-4628(19960912)61:11<1939::AID-APP8>3.0.CO;2-K10.1002/(SICI)1097-4628(19960912)61:11<1939::AID-APP8>3.0.CO;2-K ↗
17. 10.1089/end.2008.004910.1089/end.2008.0049 ↗
18. Cauda V · J Biomed Mater Res Part B Appl Biomater
19. 10.1016/S0022-5347(05)64748-910.1016/S0022-5347(05)64748-9 ↗
20. 10.1166/jnn.2015.1074710.1166/jnn.2015.10747 ↗
21. 10.1088/1748-6041/4/4/04410510.1088/1748-6041/4/4/044105 ↗
22. 10.1002/jbm.a.3228610.1002/jbm.a.32286 ↗
23. 10.1007/BF0059004210.1007/BF00590042 ↗
24. 10.1046/j.1464-410X.1997.00476.x10.1046/j.1464-410X.1997.00476.x ↗
25. 10.1046/j.1464-410X.1997.00308.x10.1046/j.1464-410X.1997.00308.x ↗
26. Tammela TLJ · Scand J Urol Nephrol Suppl · 1996 · 179 · 97
27. 10.1016/S0022-5347(05)67199-610.1016/S0022-5347(05)67199-6 ↗
28. 10.1016/S0749-8063(98)70099-410.1016/S0749-8063(98)70099-4 ↗
29. Sinha P · Polym Compos · 2016 · 39
30. 10.1016/j.eurpolymj.2012.12.01110.1016/j.eurpolymj.2012.12.011 ↗
31. 10.1007/3-540-45734-8_410.1007/3-540-45734-8_4 ↗
32. 10.1163/15685620074386910.1163/156856200743869 ↗
33. 10.1089/0892779036058734210.1089/08927790360587342 ↗
34. 10.1177/088532821769227910.1177/0885328217692279 ↗
35. 10.1016/S0022-5347(17)63130-610.1016/S0022-5347(17)63130-6 ↗
36. 10.1016/S0142-9612(02)00158-810.1016/S0142-9612(02)00158-8 ↗
37. 10.1016/S0142-9612(97)00070-710.1016/S0142-9612(97)00070-7 ↗
38. 10.1016/S0076-6879(99)10043-010.1016/S0076-6879(99)10043-0 ↗
39. 10.1016/j.biomaterials.2008.07.01410.1016/j.biomaterials.2008.07.014 ↗
40. 10.1016/j.eurpolymj.2015.12.01910.1016/j.eurpolymj.2015.12.019 ↗
41. 10.1016/j.carbpol.2009.08.03210.1016/j.carbpol.2009.08.032 ↗
42. 10.1016/S0168-3659(01)00530-210.1016/S0168-3659(01)00530-2 ↗
43. 10.1016/j.reactfunctpolym.2019.10437310.1016/j.reactfunctpolym.2019.104373 ↗
44. 10.1016/j.reactfunctpolym.2012.03.00410.1016/j.reactfunctpolym.2012.03.004 ↗
45. 10.1021/bm049921i10.1021/bm049921i ↗
46. 10.1097/01.ju.0000051160.72187.e910.1097/01.ju.0000051160.72187.e9 ↗
47. 10.1002/(SICI)1097-4636(19980315)39:4<642::AID-JBM20>3.0.CO;2-710.1002/(SICI)1097-4636(19980315)39:4<642::AID-JBM20>3.0.CO;2-7 ↗
48. 10.1211/00223570285610.1211/002235702856 ↗
49. 10.1016/S0924-8579(02)00096-110.1016/S0924-8579(02)00096-1 ↗
50. 10.1099/jmm.0.012419-010.1099/jmm.0.012419-0 ↗
51. 10.1016/S0142-9612(00)00217-910.1016/S0142-9612(00)00217-9 ↗
52. 10.1515/bmte.1997.42.s2.12310.1515/bmte.1997.42.s2.123 ↗
53. 10.1039/C8RA02912A10.1039/C8RA02912A ↗
54. 10.1016/j.jcrysgro.2018.06.02610.1016/j.jcrysgro.2018.06.026 ↗
55. 10.1016/j.juro.2017.08.08310.1016/j.juro.2017.08.083 ↗
56. 10.1007/s10856-011-4285-810.1007/s10856-011-4285-8 ↗
57. Stickler DJ · Cells Mater · 1993 · 3 · 315
58. Tunney M · Eur J Pharmaceut Sci · 1996 · 4 · S177
59. 10.1007/BF0030793910.1007/BF00307939 ↗
60. 10.1046/j.1464-410x.1998.00493.x10.1046/j.1464-410x.1998.00493.x ↗
61. Griffith DP · Investig Urol · 1976 · 13 · 346
62. 10.1002/adma.20100121510.1002/adma.201001215 ↗
63. 10.1021/la048469l10.1021/la048469l ↗
64. 10.1016/S0142-9612(97)00245-710.1016/S0142-9612(97)00245-7 ↗
65. 10.1007/s00289-010-0358-y10.1007/s00289-010-0358-y ↗
66. 10.1002/jbm.a.3205710.1002/jbm.a.32057 ↗
67. Kuo Z-K · Adv Polym Technol